FDG-PET-CT in the early response evaluation for primary systemic therapy of breast cancer-Reference-Cited by-同舟云学术

FDG-PET-CT in the early response evaluation for primary systemic therapy of breast cancer

Published:2014-04-01 Issue:2 Volume:9 Page:306-312
ISSN:2391-5463
Container-title:Open Medicine
language:
Short-container-title:

Author:

Tőkés Tímea¹,Torgyík László¹,Kulka Janina²,Borka Katalin²,Szász Attila²,Tóth Andrea¹,Harsányi László³,Lengyel Zsolt⁴,Györke Tamás,Dank Magdolna¹

Affiliation:

1. 11st Department of Internal Medicine, Oncology Division Semmelweis University, Hungary, Budapest, 1083, Tömő u. 25-29

2. 22nd Department of Pathology, Semmelweis University, Hungary, Budapest, 1091, Üllői út 93

3. 31st Department of Surgery, Semmelweis University, Hungary, Budapest, 1082, Üllői út 78

4. 4Pozitron Diagnostics Ltd. Budapest, Hungary, Budapest, 1117, Hunyadi J. út 9

Abstract

AbstractPrimary systemic therapy (PST) is a standard treatment for patients with locally advanced breast cancer. We report one of our patients to demonstrate the optimal use of FDG-PET-CT in the routine clinical workup during PST, especially when clinicians face contradictory clinical and pathological findings, and to show the advantages of this imaging modality in the decision-making process about the initial treatment choice. By reviewing the literature we would also like to confirm that FDG-PET-CT is highly sensitive in the measurement of the early therapeutic response and the prediction of the complete pathological remission, as early as after the first cycle of chemotherapy is administered.

Publisher

Walter de Gruyter GmbH

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.2478/s11536-013-0268-0.pdf

Reference37 articles.

1. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol, 2003, 21, 2600–2608

2. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol, 2006, 24, 1940–1949

3. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst, 1990, 82, 1539–1545

4. Kulka J, Tokes AM, Toth AI, Szasz AM, Farkas A, Borka K et al. [Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy]. Magy Onkol, 2009, 53, 335–343

5. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol, 1998, 16, 2672–2685